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 Background Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging 
system. We investigated if four well-documented gene expression risk scores can improve patient stratification.
 Methods Microarray-based versions of risk-scores were applied to a large independent cohort of 688 stage II/III tumors 
from the PETACC-3 trial. Prognostic value for relapse-free survival (RFS), survival after relapse (SAR), and overall 
survival (OS) was assessed by regression analysis. To assess improvement over a reference, prognostic model 
was assessed with the area under curve (AUC) of receiver operating characteristic (ROC) curves. All statistical 
tests were two-sided, except the AUC increase.
 Results All four risk scores (RSs) showed a statistically significant association (single-test, P < .0167) with OS or RFS in uni-
variate models, but with HRs below 1.38 per interquartile range. Three scores were predictors of shorter RFS, one of 
shorter SAR. Each RS could only marginally improve an RFS or OS model with the known factors T-stage, N-stage, 
and microsatellite instability (MSI) status (AUC gains < 0.025 units). The pairwise interscore discordance was never 
high (maximal Spearman correlation = 0.563) A combined score showed a trend to higher prognostic value and 
higher AUC increase for OS (HR = 1.74, 95% confidence interval [CI] = 1.44 to 2.10, P < .001, AUC from 0.6918 to 
0.7321) and RFS (HR = 1.56, 95% CI = 1.33 to 1.84, P < .001, AUC from 0.6723 to 0.6945) than any single score.
 Conclusions The four tested gene expression–based risk scores provide prognostic information but contribute only margin-
ally to improving models based on established risk factors. A combination of the risk scores might provide more 
robust information. Predictors of RFS and SAR might need to be different.
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For the management of primary colon cancer (CC), evidence-
based (T-stage Node Metastasis [TNM] and other criteria) guide-
lines propose adjuvant chemotherapy for stage III cases and for 
high-risk subgroups of stage II (1). Recently published gene expres-
sion–based risk scores (RSs), which use a combination of genes, 
purportedly contribute additional prognostic information, and 
allow a better definition of levels of risk (2–12). These models 
were internally validated using data-resampling techniques. The 
potential bias that might result from effects accidentally present in 
a dataset but not in the relevant overall population should be ruled 
out in one or multiple independent cohorts, because this bias defies 
internal validation techniques (13). An important element is confir-
mation on formalin fixed paraffin embedded (FFPE) tissues, as this 
remains the standard in terms of routinely available test samples. 
This should be done without redefinition of the weight given to 
individual genes to optimally fit the new data, as this would affect 
the new risk assessment.
In view of introducing an RS for real clinical applications, a cru-
cial issue is to test and compare the prognostic value of the differ-
ent gene sets and scoring models when applied to the same data 
generated with a uniform technology and tested in models that also 
contain the other known risk-factors. Also of high interest is inves-
tigating to what extent they concord in risk assessment at the level 
of the individual patient (14).
We tested four well-documented RSs (Table 1), available with a 
scoring formula sufficiently detailed to make them assessable. The 
seven-gene signature developed by Genomic Health (GHS) (9) is 
of special interest because it was derived from a large collection of 
data, was since tested in two confirmation studies (15,16), and its 
routine use is being promoted. This RS was obtained on about 1800 
stage II-III tumors from multiple studies (9). The prognostic effects 
of virtually all of the tested genes appeared not to be different for 
stage II and stage III tumors. The higher rate of relapse in node-
positive stage III allowed the identification of risk genes for relapse, 
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which then appeared to be prognostic also in stage II. The RS pro-
posed by Veridex (VDS) (5) uses seven genes derived from 123 stage 
II tumors by reducing an initially proposed 23-gene signature (12) 
developed on 74 stage II tumors. The Almac (ALM) RS (7) was 
developed on 215 stage II cases, with 634 probe sets representing 
477 genes of their CC Disease Specific Array. The RS proposed by 
Oh et al. (10), which we call the MDA (MD Anderson) system, uses 
114 probe sets, representing 86 genes. This RS was developed on 
a heterogeneous training set of 177 cases that included stage I-IV 
patients, with very short survival times in stage IV cases and select-
ing for genes that separated two main groups obtained by unsu-
pervised clustering, rather than selecting genes associated with a 
prespecified survival endpoint. This RS was validated on an inde-
pendent, publically available data set of 213 stage I-IV patients (10).
To compare the prognostic value of the individual RSs when 
used with the same microarray data from FFPE material and assess 
their concordance, we tested them on a single independent large 
homogeneous CC cohort as stand-alone risk indicators, as com-
bined risk indicators, and in combination with several established 
clinico-pathological prognostic variables.
Methods
Patients and Samples
The PETACC-3 (EORTC 40993)  is a multicenter pan-European 
study that included patients aged 18 to 75  years, with completely 
resected, histologically-proven, stage II-III colonic adenocarcinoma, 
as described previously (17). After providing written informed consent 
in which the planned translational study program was clearly specified, 
patients were randomized to receive six months of 5-FU/FA either 
alone or in combination with irinotecan (see also Supplementary 
Materials, available online) and then followed regularly. The trial 
results were negative (17). The procedures used to establish patho-
logical and molecular features, including microsatellite instability 
(MSI) (18), RNA extraction from FFPE tissue samples (19), as well as 
analysis of prognostic markers (18,20), have been reported previously. 
TNM staging was according to the AJCC 5th edition guidelines of 
1997. The translational research program was reviewed by the ethical 
committee of each institution participating to the trial.
Gene Expression Data Cohort
Array-based gene expression data were previously obtained (21) 
from the PETACC-3 trial biobank (17–19) using the Almac micro-
arrays ADXCRC (Almac, Craigavon, UK; ArrayExpress accession: 
A-AFFY-101). Of the 1404 patients in the biobank, profiling was 
undertaken for 1130: all 984 stage III cases, the 73 stage II cases 
with an relapse-free survival (RFS) event and the same number of 
randomly selected nonrelapsers. Final quality control was passed by 
samples representing 688 patients (60.9%, 108 stage II, 580 stage 
III) (Supplementary Materials, available online). The study cohort 
is similar to the trial cohort, except for a lower proportion of stage II 
cases and an increase of cases with an RFS event inside this stratum 
(Supplementary Table 1, available online). We report the results on 
the 688 cohort (ArrayExpress accession: E-MTAB-990); results on 
the 580 stage III populations gave identical conclusions (not shown).
Risk Score Computation
We computed the ALM RS (7) exactly and approximative (“a”) 
versions to the RSs of Genomic Health (aGHS) (9), Veridex 
(aVDS) (5), and MD Anderson (aMDA) (10) (Table 1). Coefficients 
(Supplementary Table 2, available online) were set so that higher 
scores are used for higher risk; more information is given in the 
Supplementary Methods (available online). The ALM RS was 
reproduced using the original ADXCRC probe sets and coeffi-
cients. For the other RSs, the prefix “a” is used to indicate approxi-
mation because the scores were not computed with the original 
measurement systems. Of the 114 probe sets of the MDA RS, 110 
could be mapped to 86 unique entries (Entrez GeneIDs) in the 
RefSeq database, of which 85 were represented on the ADXCRC 
platform. For aVDS, no probe set for the CAPG gene was avail-
able, and only the remaining six genes were used.
To assess if the information from the RSs could be usefully 
aggregated, a combined score called CS4 was computed by calcu-
lating the rescaled arithmetic average of the scores (median-cen-
tered, scaled to interquartile range [IQR] = 1).
Pairwise percentages of agreement between RSs were deter-
mined by splitting each RS at its median and counting the pro-
portion of patients classified in the same risk group (high or low). 
Furthermore, in order to have threshold-independent agreement 
measures, pairwise Spearman correlations were computed.
Statistical Analysis
Analyses were performed using the R software system for statisti-
cal computing, version 2.14.0 (22). Associations between clinical 
outcomes and categorical or continuous variables were computed 
using Cox proportional hazard regression. The proportionality 
assumption was verified with plots of Schoenfeld residuals. Hazard 
ratios (HRs) reported for continuous variables were referred to one 
Table 1. Description of the four risk scores analyzed*
Abbreviation
Risk scores
GHS VDS MDA ALM
Developer Genomic Health Veridex MD Anderson ALMAC diagnostics
Type of assay Q-RT-PCR microarray and Q-RT-PCR microarray microarray
Type of tissue FFPE fresh frozen and FFPE fresh frozen FFPE
Main publication O’Connell et al. 2010. Jiang et al. 2008. Oh et al. 2011. Kennedy et al. 2011.
Total number of features 7 7 114 (86 genes) 634 (482 genes)
Features used (genes) 7 6 85 (85 genes) 634 (identical platform)
* ALM = the scoring system proposed by Almac researchers; GHS = scoring system proposed by Genomic Health researchers; FFPE = formalin fixed paraffin 
embedded; MDA = scoring system proposed by researchers from MD Anderson Cancer Center; Q-RT-PCR = quantitative real-time PCR (Q-RT-PCR); VDS = scoring 
system proposed by Veridex researchers.
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IQR. Confidence intervals and P values for the HR were computed 
using the Wald test statistic.
Receiver operating characteristic (ROC) curves and area under 
curve (AUC) values were computed with the “survivalROC” pack-
age (23), using prognostic models fitted with Cox regression and 
the Kaplan–Meier method to fit the joint distribution of RS and 
time; statistical significance was assessed by permuting the RS 
across patients to obtain the distribution under the null hypoth-
esis of no prognostic information. Harrell’s Concordance Index for 
censored survival data, the fraction of pairs of patients whose pre-
dicted survival times are correctly ordered (24), was computed with 
“survival” package.
We report single-test two-sided P values, except for the test on 
increase of AUC, which is one-sided.
results
Gene expression profiles of an independent cohort of 688 
stage II/III patients with a median follow-up of 69  months (21) 
(Supplementary Methods and Supplementary Table  1, available 
online) were used to test the prognostic value of four proposed 
risk-scoring methods (Table  1). One reproduced exactly (ALM), 
three approximately (a-versions of GHS, VDX, MDA).
In terms of the genes considered, the four gene signatures had 
little overlap: five of the 86 genes used by MDA are in the 477-gene 
ALM signature, and only one is among the seven genes used by 
GHS (Figure 1). This does not exclude score concordance, if the 
different gene sets share a similar expression profile.
Prognostic Value of Risk Scores
We first tested the association of each scoring system with out-
come (Table 2) using the same survival regression approach as in 
the previous studies. The assessment was conducted using continu-
ous scores, which is preferable for interassay evaluation, rather than 
the use of arbitrary subgroups, unless the latter are appropriately 
predefined (25).
In agreement with originally published data, higher values 
of each RS were associated with shorter survival after diagno-
sis (at least overall survival [OS] or RFS), statistically significant 
(Bonferroni correction for three tested endpoints: P ≤ .05/3 = .0167) 
(Table 2). The effect sizes were moderate (HR < 1.38 for variation 
of one IQR). The prognostic value for OS of each RS was only 
weakly modified in multivariable models, adjusted for the T-stage, 
N-stage, MSI status, and additional factors (see Table 2). The ALM 
score appeared to be the strongest in univariate models (HR = 1.38, 
95% confidence interval [CI] = 1.16 to 1.65, P < .001), but lost part 
of its prognostic value in the multivariable model (HR = 1.22, 95% 
CI = 1.02 to 1.47, P = .03). Slightly weaker than the others in the 
univariate model, aVDS was the single RS to lose statistical sig-
nificance (P = .07). Survival proportions at three years for low- and 
high-risk groups obtained by cutting at the median of each RS are 
given in Table  3, their survival curves in Supplementary Figures 
2–4 (available online).
For the prediction of RFS (Table 2), aGHS and ALM had P ≤ 
.001; aVDS was close (P = .002), which we take as confirming evi-
dence for a real association with relapse. These three scores showed 
similar HRs, close to 1.30 and 95% confidence intervals ranging 
between 1.10 and 1.60. Adding the ALM score to a set of estab-
lished risk factors slightly reduced its prognostic value, probably 
because of an effect of the inclusion of MSI-H status, with which it 
is negatively associated (Supplementary Figure 1, available online). 
In contrast, aMDA was positively associated with MSI-H status; 
its association with RFS was borderline statistically significant in 
the univariate and multivariable models in the MSS subpopulation 
(data not shown), but not in the full cohort.
Uniquely, aMDA was stronger in predicting OS than RFS, 
and it was the only strong predictor of survival after relapse 
(SAR) (HR  =  1.81, 95% CI  =  1.45 to 2.27, P < .001) (Table  2). 
Multivariable and univariate models for SAR gave similar HR esti-
mates (Table 2).
Patient Classification and Improvement on a Reference 
Clinical Model
To investigate the ability to risk-classify at the patient level, we 
cross-classified each RS quartile group with RFS outcome classes, 
where absence of relapse in five years was considered good and a 
relapse within three years was considered poor outcome (Table 4). 
This table shows that 20–30% of the patients considered low risk 
(lowest quartile) by the scores are relapsing at three years, and, con-
versely, 48%-58% of the patients considered at the highest risk of 
relapse by the scores are relapse free (and probably cured) at five 
years, when no other risk factors are considered. More important 
to be useful in clinic, an RS should contribute to better classify 
patients compared with a survival model based on known risk fac-
tors (TNM and MSI status). We evaluated this potential improve-
ment in analyzing the AUC of time-dependent ROC curves (23) 
at three years. The improvement in AUC obtained by adding each 
RS to a reference model with T-stage, N-stage, and MSI did not 
exceed 0.025 units (Figure 2; Table 5). While these results depend 
on the particular time point, they are indicative of the new prog-
nostic information that the tested RSs can provide. A time-inde-
pendent assessment is provided by Harrell’s concordance index 
(Supplementary Table  3, available online); tests for an improve-
ment in the concordance index were consistent with those for AUC 
at three years.
Concordance Analysis
Only a small proportion of the total survival variability was 
explained by the RSs (see R2 statistics, Supplementary Table  4, 
available online). This raises the question if the relatively small 
prognostic information being caught by each RS was the same.
Figure 1. Gene List Overlaps. Venn diagram representing the number of 
genes unique or in common, among those selected in the original stud-
ies for computing the risk scores.
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Overall, the RSs concurred poorly. The ALM RS showed very 
little correlation with any of the other scores. Division of the cohort 
into equally sized high and low-risk groups (Table 6) resulted in 
the ALM classification to agree for about 50% of the patients 
with that of any other signature, as expected by chance for uncor-
related classifiers. The highest positive Spearman correlation was 
between aGHS and aMDA scores (rho = 0.563, 95% CI = 0.509 to 
0.612), with moderate agreement (70.3%). The aVDS score was 
negatively correlated with the two other scores (particularly with 
aMDA, Spearman correlation rho =  -0.443, 95% CI =  -0.501 to 
-0.381), resulting in agreements of only 33.1% (aMDA) and 37.5% 
(aGHS).
Table 3. Three-year survival
Marker Risk group
RFS SAR OS
% (95% CI) * % (95% CI) * % (95% CI) *
Whole cohort (N = 688) 66.9 (63.5 to 70.5) 34.4 (28.7 to 41.2) 83.4 (80.6 to 86.2)
aGHS
low 69.6 (64.9 to 74.7) 40.7 (32.4 to 51.2) 86.5 (83.0 to 90.2)
high 64.2 (59.4 to 69.5) 28.5 (21.3 to 38.0) 80.2 (76.1 to 84.5)
aVDS
low 70.9 (66.2 to 75.8) 30.0 (21.8 to 41.1) 83.4 (79.5 to 87.4)
high 63.0 (58.1 to 68.3) 37.6 (30.2 to 46.7) 83.4 (79.5 to 87.4)
aMDA
low 69.1 (64.3 to 74.1) 49.8 (41.2 to 60.1) 88.3 (84.9 to 91.8)
high 64.8 (60.0 to 70.1) 19.9 (13.6 to 28.9) 78.5 (74.2 to 82.9)
ALM
low 70.8 (66.1 to 75.8) 36.8 (28.3 to 47.8) 86.6 (83.0 to 90.2)
high 63.1 (58.2 to 68.4) 32.4 (25.1 to 41.6) 80.2 (76.1 to 84.5)
CS4
low 70.5 (65.8 to 75.5) 41.8 (33.1 to 52.9) 87.4 (84.0 to 91.0)
high 63.4 (58.5 to 68.7) 28.7 (21.8 to 37.8) 79.3 (75.2 to 83.7)
* Estimated proportions of three-year survival (percentage) by the Kaplan-Meier method with 95% confidence intervals for the whole cohort and for risk groups 
defined by splitting the cohort at the median of each risk score into equally sized subgroups. aGHS = microarray-based approximation of the scoring system 
proposed by Genomic Health researchers; ALM = the scoring system proposed by Almac researchers; aMDA = approximation of the scoring system proposed by 
researchers from MD Anderson Cancer Center; aVDS = approximation of the scoring system proposed by Veridex researchers; CI = confidence interval; CS4 = the 
scoring system obtained by combining the four existing systems; OS = overall survival; RFS = relapse-free survival; SAR = survival after relapse.
Table 2. Cox models estimates
Outcome Marker  
Univariate* Multivariable*†
HR (95% CI) P‡ HR (95% CI) P‡
RFS
aGHS 1.33 (1.13 to 1.56) <.001 1.30 (1.11 to 1.53) .001
aVDS 1.29 (1.10 to 1.52) .002 1.27 (1.07 to 1.51) .007
aMDA 1.10 (0.93 to 1.30) .26 1.13 (0.93 to 1.37) .22
ALM 1.31 (1.13 to 1.53) <.001 1.20 (1.02 to 1.40) .03
CS4§ 1.56 (1.33 to 1.84) <.001 1.45 (1.23 to 1.71) <.001
SAR
aGHS 1.16 (0.95 to 1.43) .14 1.16 (0.92 to 1.46) .20
aVDS 0.90 (0.72 to 1.13) .38 0.84 (0.66 to 1.08) .17
aMDA 1.81 (1.45 to 2.27) <.001 1.89 (1.46 to 2.46) <.001
ALM 1.19 (0.97 to 1.47) .10 1.10 (0.88 to 1.36) .40
CS4§ 1.46 (1.18 to 1.82) <.001 1.33 (1.05 to 1.67) .017
OS
aGHS 1.36 (1.13 to 1.64) .001 1.34 (1.10 to 1.62) .003
aVDS 1.24 (1.03 to 1.50) .02 1.21 (0.99 to 1.48) .07
aMDA 1.31 (1.08 to 1.58) .006 1.37 (1.09 to 1.71) .007
ALM 1.38 (1.16 to 1.65) <.001 1.22 (1.02 to 1.47) .03
CS4§ 1.74 (1.44 to 2.10) <.001   1.57 (1.29 to 1.91) <.001  
* Cox proportional hazards regression models were used to estimate hazard ratios for one interquartile range variation of the continuous risk scores; no stratification 
was applied; adjustment by treatment was applied only in the multivariable models. aGHS = microarray-based approximation of the scoring system proposed by 
Genomic Health researchers; ALM = the scoring system proposed by Almac researchers; aMDA = approximation of the scoring system proposed by researchers 
from MD Anderson Cancer Center; aVDS = approximation of the scoring system proposed by Veridex researchers; CI = confidence interval; CS4 = the scoring 
system obtained by combining the four existing systems; HR = hazard ratio; OS = overall survival; RFS = relapse-free survival; SAR = survival after relapse.
† Each multivariable model included one gene expression risk score and the following variables: age, gender, TNM staging (T-stage, N-stage) (27), grade, location 
(right = proximal, left = distal), treatment arm, presence of lymphovascular invasion, and microsatellite instability (MSI) status.
‡ Shown are single-test P values. The statistical significance cutoff by the Bonferroni principle (considering three tests) is at 0.05/3 = 0.0167.
§ CS4 is a combined score obtained by averaging the four original risk scores.
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Combined Risk Score
Given that the four scores define different prognostic information, 
we tested if they could be combined. Interestingly, a combination 
score (CS4, the average of the four RSs) was more strongly associ-
ated with RFS and OS than each individual score in the regres-
sion models (HR = 1.74, 95% CI = 1.44 to 2.10 for OS, P < .001; 
HR = 1.56, 95%CI = 1.33 to 1.84 for RFS, P < .001; similar HRs 
in the multivariable models) (Table 2), and CS4 also contributed 
a stronger but still moderate AUC improvement to the reference 
model for RFS (0.6723 to 0.6945) and OS (0.6918 to 0.7321) 
(Table 5). CS4 showed a weaker association with the SAR endpoint 
than MDA, but still statistically significant.
Discussion
We assessed the prognostic information content of four RSs in 
a uniform setting (same data, same technical platform) and in an 
independent patient cohort. Routine application of an RS would 
likely be on FFPE material, as in this study. The PETACC-3 tissue 
samples originate from a large number of pathology departments, 
each with their own variations in tissue processing—which closely 
imitate a routine clinical setting. In this setting, the RSs improved 
prognostic models containing standard risk factors for at least one 
endpoint, both in a regression analysis and in an ROC-AUC analy-
sis. This confirms their potential relevance for clinical application. 
The small improvements contributed to a model with known risk 
factors question, though, if the RSs can be of high relevance.
The discordance we observed suggests that the four RSs use 
genes representing different risk-associated molecular motifs 
identifying different subsets of patients with increased risk. The 
simplest combination, the average of the four scores (CS4), is 
prognostic for all three endpoints and the strongest for both RFS 
and OS. The lack of convergence between the RSs might appear 
surprising at first, considering that ALM, GHS, and VDS selected 
genes following a similar strategy. Several reasons suggest why sim-
ilar RS studies can result in such discordant gene sets. First, even 
in relatively large studies like GHS, the measures of association of 
gene expression levels with survival based on regression models are 
not precise enough to allow for a definitive ranking of the many 
genes in the human genome (26). Unstable risk ranking causes 
differences in selected genes, even if the study design is identical. 
The MDA RS is the only one that was derived from a population 
including stage IV patients. Likely, it is driven by pathways that are 
associated with malignant progression and treatment resistance of 
metastatic lesions rather than the development of metastases from 
a primary tumor site, and these pathways are different. This might 
be one reason why MDA was the only of four RSs predicting statis-
tically significantly SAR.
For RFS and SAR it might not be possible to find a unique opti-
mal RS, and for OS one might need to combine scores that use dif-
ferent genes. The CS4 takes a step in that direction and performs 
better than each of the four RSs for OS.
This study has some limitations. A question is whether or not 
the approximations we used for aGHS, aVDS, and aMDA might 
Table 4. Concordance by risk score and endpoint groups*
Scoring method Risk score subgroup
Actual survival group
Poor Good Rest
aGHS
Q1 46 (26.7%) 116 (67.4%) 10 (5.8%)
Q2 58 (33.7%) 103 (59.9%) 11 (6.4%)
Q3 54 (31.4%) 105 (61.0%) 13 (7.5%)
Q4 69 (40.1%)  84 (48.8%) 19 (11.1%)
aVDS
Q1 40 (23.3%) 117 (68.0%) 15 (8.7%)
Q2 60 (34.9%) 101 (58.7%) 11 (6.4%)
Q3 63 (36.6%)  96 (55.8%) 13 (7.5%)
Q4 64 (37.2%)  94 (54.7%) 14 (8.2%)
aMDA
Q1 51 (29.7%) 109 (63.4%) 12 (7.0%)
Q2 55 (32.0%) 100 (58.1%) 17 (9.9%)
Q3 62 (36.0%) 100 (58.1%) 10 (5.9%)
Q4 59 (34.3%)  99 (57.6%) 14 (8.1%)
ALM
Q1 50 (29.1%) 110 (64.0%) 12 (7.0%)
Q2 50 (29.1%) 109 (63.4%) 13 (7.6%)
Q3 54 (31.4%) 103 (59.9%) 15 (8.7%)
Q4 73 (42.4%)  86 (50.0%) 13 (7.5%)
CS4
Q1 36 (20.9%) 123 (71.5%) 13 (7.6%)
Q2 65 (37.8%) 100 (58.1%)  7 (4.1%)
Q3 57 (33.1%) 100 (58.1%) 15 (8.7%)
Q4 69 (40.1%)  85 (49.4%) 18 (10.4%)
* Patients were classified into four equally sized risk-score quartile subgroups (Q1: lowest predicted relapse risk, Q4: highest predicted relapse risk) and into actual 
survival groups (good: follow-up without relapse for at least five years; poor: relapse in the first three years; rest: otherwise (relapse between three and five years 
or censoring before five years without event). aGHS = microarray-based approximation of the scoring system proposed by Genomic Health researchers; ALM = the 
scoring system proposed by Almac researchers; aMDA = approximation of the scoring system proposed by researchers from MD Anderson Cancer Center; 
aVDS = approximation of the scoring system proposed by Veridex researchers; CS4 = the scoring system obtained by combining the four existing systems.
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have altered the sense of the RSs. An alteration could be because 
of diverse factors: gene expression was measured with microarrays 
(GHS: by RT-PCR) from FFPE material (MDA: fresh-frozen), 
and not all genes were available (VDA: 6/7, MDA: 85/86, see 
Methods). Moreover, the cohort is mostly a stage III European 
CC population selected to undergo chemotherapy. For aGHS, the 
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Figure 2. Receiver operating characteristic (ROC) curves and area under 
curve (AUC) values. Time-dependent ROC curves and AUC values were 
computed at t  =  3  years for a reference prognostic model based on 
known risk factors (red) and with the addition of the indicated risk scores 
(black), for the three endpoints: overall survival (OS), relapse-free sur-
vival (RFS), and survival after relapse (SAR). The factors included in the 
reference model were T-stage ((T1 or T2)-T3-T4), N-stage (N0-N1-N2), 
and MSI-status. Indicated are the AUC value of the reference model and 
the increment in AUC (delta-AUC), obtained by adding the risk score 
(see also Table 5). The P value was computed with a permutation test 
for the null of hypothesis of no increment in AUC when adding the risk 
score (one-sided test).
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biological function of the genes is well documented, and, in our 
microarray profiles, the genes most positively correlated with the 
risk score (“stroma-EMT”) and those most negatively correlated 
(proliferation genes) were the same, suggesting that the original 
GHS would rank the patients in a very similar way as aGHS. For 
large gene sets (ALM, aMDA), it is unlikely that the relative scor-
ing of patients would be sensitive to the technology used; for aVDS 
(six out of seven genes), this is less obvious.
The prognostic effects we found for aGHS in the survival 
regression model are similar to those observed in the large valida-
tion study based on patients in the QUASAR trial (15). The stand-
ardized HRs for RFS were in close agreement (univariate HR per 
IQR = 1.38, 95% CI = 1.11 to 1.74), suggesting that the difference 
in technology did not markedly impact the estimated prognostic 
value. In the study of Gray (15), the reported HR for GHS was 
determined in a cohort of stage II patients that underwent surgery 
without chemotherapy. The HR estimated in the patient group 
randomized to fluorouracil/folinic acid was similar. The pooled 
estimate (HR per IQR = 1.29, 95% CI = 1.09 to 1.52) was very 
close to what we report here (HR per IQR = 1.30, 95% CI = 1.11 
to 1.53). This suggests a similar prognostic value in cohorts with 
or without 5-FU based chemotherapy. We contend that our results 
are relevant for assessing the state of research in prognostic gene-
expression signatures for the typical CC population.
Note that we report statistical significance without full adjust-
ment for multiple testing; we proceeded as if each RS would be 
tested by itself. Under the hypothesis that no RS has association 
with outcome, there is therefore in this study a higher risk to be 
wrongly reporting at least one statistically significant association 
(type I error). Since each RS had previously passed a test of statisti-
cal significance in the original study, we found this preferable to a 
more stringent statistical cutoff that would raise the risk of false 
negative conclusions (type II error).
In summary, we tested the prognostic value of four RSs on micro-
array gene expression data from routinely collected FFPE material. 
We found that they are associated with survival endpoints but that 
they are discordant and seem to add little to risk models with known 
risk factors. The good performance of CS4 suggest that there might 
still be more information in gene expression profiles than is being 
extracted by the four RSs tested here, and future work and larger 
datasets might allow finding a stronger prognostic signature in CC.
Table 5. Time-dependent receiver operating characteristic curves, 
area under curve (time = 3 years) by endpoint and risk score
Endpoint Marker AUC (ref. model) * AUC gain* P†
RFS 0.6723
aGHS 0.0136 .04
aVDS 0.0185 .009
aMDA 0.0085 .17
ALM 0.0089 .16
CS4 0.0222 .0008
SAR 0.6406
aGHS 0.0192 .11
aVDS -0.0001 .79
aMDA 0.0838 .0001
ALM 0.0053 .54
CS4 0.0443 .005
OS 0.6918
aGHS 0.0187 .005
aVDS 0.0135 .03
aMDA 0.0243 .001
ALM 0.0140 .02
CS4 0.0403 .0001
* Area under curve (AUC) for predicting survival status at three years was 
computed by risk scoring methods and endpoint. A reference model was 
fitted using the predictor variables N-stage, T-stage, and MSI status. The AUC 
gain was computed by adding the gene expression risk score to the predictor 
variables in the model. aGHS = microarray-based approximation of the scoring 
system proposed by Genomic Health researchers; ALM = the scoring system 
proposed by Almac researchers; aMDA = approximation of the scoring system 
proposed by researchers from MD Anderson Cancer Center; AUC = area 
under curve; aVDS = approximation of the scoring system proposed by 
Veridex researchers; CS4 = the scoring system obtained by combining the 
four existing systems; OS = overall survival; RFS = relapse-free survival; 
SAR = survival after relapse.
† Statistical significance against the null hypothesis of no increase was 
determined by the permutation method. By construction, the minimal P 
value that can be reached is .0001 (bold), as they were based on 10’000 
permutations, and estimated as: (#(permuted deltaAUCs > observed 
deltaAUC) + 1) / (# permutations + 1); this is by definition a one-sided test, as 
the model can only improve when adding the RS.
Table 6. Pairwise agreements and correlations between risk scores
aGHS (95% CI) aVDS (95% CI) aMDA (95% CI) ALM (95% CI) CS4 (95% CI)
aGHS -0.318* 0.563 0.187 0.662
(-0.383 to -0.249) (0.509 to 0.612) (0.114 to 0.258) (0.618 to 0.702)
aVDS 37.5%† -0.443 0.071 0.145
(33.9% to 41.3%) (-0.501 to -0.381) (-0.004 to 0.145) (0.071 to 0.218)
aMDA 70.3% 33.1% 0.125 0.573
(66.8% to 73.7%) (29.7% to 36.8%) (0.050 to 0.197) (0.521 to 0.621)
ALM 57.8% 49.1% 54.1% 0.652
(54.1% to 61.6%) (45.3% to 52.9%) (50.3% to 57.8%) (0.607 to 0.693)
CS4 75.3% 52.9% 70.1% 72.4%
(71.9% to 78.4%) (49.1% to 56.7%) (66.5% to 73.4%) (68.9% to 75.7%)
* Above the diagonal, pairwise Spearman correlations between the continuous risk scores, with 95% confidence intervals in parentheses. aGHS = microarray-based 
approximation of the scoring system proposed by Genomic Health researchers; ALM = the scoring system proposed by Almac researchers; aMDA = approximation 
of the scoring system proposed by researchers from MD Anderson Cancer Center; aVDS = approximation of the scoring system proposed by Veridex researchers; 
CI = confidence interval; CS4 = the scoring system obtained by combining the four existing systems.
† Below the diagonal, pairwise percentage of agreement between risk scores, as given by splitting the continuous scores at their medians, with 95% confidence 
intervals in parentheses.
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